SummaryJoin Avalere’s panel of data analytics, market access, and policy experts for a discussion on the potential for federal drug pricing reform in Congress or via administrative action.
With Congress poised to consider a second reconciliation package, drug pricing reforms are likely to be on the agenda as a means to pay for permanent coverage expansion and other top priorities. In addition to the expected legislative landscape and as the Biden Administration takes shape, the debate over drug pricing reforms, especially “government negotiation,” is likely to reignite through CMMI and other regulatory vehicles.
- Part D redesign
- Government negotiation
- International reference pricing
- Linking payment to evidence and value
- Part B drug reimbursement changes
- Inflation rebates
produces measurable results. Let's work together.